Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer

Gynecologic Oncology

Volumn 114, Issue 1, 2009, Pages 105-110

  de Jong, R A ^a   Leffers, N ^a   Boezen, H M ^a   ten Hoor, K A ^a   van der Zee, A G J ^a   Hollema, H ^a   Nijman, H W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cytotoxic T lymphocyte; Endometrial cancer; Tumor infiltrating lymphocytes

Indexed keywords

CD45RO ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; SALPINGOOOPHORECTOMY; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD; ANTIGENS, CD45; CD8-POSITIVE T-LYMPHOCYTES; ENDOMETRIAL NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODE EXCISION; LYMPHOCYTES, TUMOR-INFILTRATING; MICROARRAY ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; SURVIVORS; T-LYMPHOCYTES;

EID: 67349085248     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.03.022     Document Type: Article

References (34)

1. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., and Vergote I. Endometrial cancer. Lancet 366 9484 (2005 Aug 6) 491-505
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA. Cancer J. Clin. 58 2 (2008 Mar) 71-96
3. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 15 1 (1983 Feb) 10-17
4. Clemente C.G., Mihm Jr. M.C., Bufalino R., Zurrida S., Collini P., and Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77 7 (1996 Apr 1) 1303-1310
5. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006 Sep 29) 1960-1964
6. Halpern A.C., and Schuchter L.M. Prognostic models in melanoma. Semin. Oncol. 24 1 Suppl 4 (1997 Feb) S2-S7
7. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 51 (2005 Dec 20) 18538-18543
8. Vesalainen S., Lipponen P., Talja M., and Syrjanen K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 30A 12 (1994) 1797-1803
9. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348 3 (2003 Jan 16) 203-213
10. + T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 10 13 (2004 Jul 1) 4450-4456
11. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 58 16 (1998 Aug 15) 3491-3494
12. Wolf A.M., Wolf D., Steurer M., Gastl G., Gunsilius E., and Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9 2 (2003 Feb) 606-612
13. + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
14. + Tregs and immune control. J. Clin. Invest. 114 9 (2004 Nov) 1209-1217
15. Yamaguchi T., and Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin. Cancer Biol. 16 2 (2006 Apr) 115-123
16. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 9 (2004 Sep) 942-949
17. Kono K., Kawaida H., Takahashi A., Sugai H., Mimura K., Miyagawa N., et al. CD4(+)CD25 high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol. Immunother. 55 9 (2006 Sep) 1064-1071
18. + regulatory T cells in the peripheral circulation of patients with head and neck cancer. Br. J. Cancer 92 5 (2005 Mar 14) 913-920
19. Bates G.J., Fox S.B., Han C., Leek R.D., Garcia J.F., Harris A.L., et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 24 34 (2006 Dec 1) 5373-5380
20. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 12 (2001 Jun 15) 4766-4772
21. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 23 (2005 Dec 1) 8326-8331
22. + tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 67 1 (2007 Jan 1) 354-361
23. Pages F., Berger A., Camus M., Sanchez-Cabo F., Costes A., Molidor R., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353 25 (2005 Dec 22) 2654-2666
24. Fattorossi A., Battaglia A., Ferrandina G., Buzzonetti A., Legge F., Salutari V., et al. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol. Oncol. 92 1 (2004 Jan) 106-115
25. + lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol. Oncol. 110 2 (2008 Aug) 216-221
26. Ino K., Yamamoto E., Shibata K., Kajiyama H., Yoshida N., Terauchi M., et al. Inverse Correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival. Clin. Cancer Res. 14 8 (2008 Apr 15) 2310-2317
27. Scholten A.N., van Putten W.L., Beerman H., Smit V.T., Koper P.C., Lybeert M.L., et al. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEC trial with central pathology review. Int. J. Radiat. Oncol. Biol. Phys. 63 3 (2005 Nov 1) 834-838
28. Tavassoli FA, Devilee P. World Health Organization: Tumours of the Breast and Female Genital Organs (WHO Classification of Tumours). 1 ed. IARCPress-WHO; 2003.
29. Cancer Comittee of the International Federation of Gynaecology and Obstetrics (1986). Gynecol. Oncol. 25 (2008) 383-385
30. Kononen J., Bubendorf L., Kallioniemi A., Barlund M., Schraml P., Leighton S., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4 7 (1998 Jul) 844-847
31. Han L.Y., Fletcher M.S., Urbauer D.L., Mueller P., Landen C.N., Kamat A.A., et al. HLA class I antigen processing machinery component expression and intratumoral T-cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res. 14 11 (2008 Jun 1) 3372-3379
32. Hori S., Nomura T., and Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 5609 (2003 Feb 14) 1057-1061
33. Nair S., Boczkowski D., Fassnacht M., Pisetsky D., and Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 67 1 (2007 Jan 1) 371-380
34. Santin A.D., Bellone S., Ravaggi A., Roman J.J., Pecorelli S., Parham G.P., et al. Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br. J. Cancer 86 1 (2002 Jan 7) 151-157